These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2908030)

  • 1. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.
    Rasmussen C; Bergh T; Wide L; Brownell J
    Clin Endocrinol (Oxf); 1988 Sep; 29(3):271-9. PubMed ID: 2908030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia.
    Homburg R; West C; Brownell J; Jacobs HS
    Clin Endocrinol (Oxf); 1990 May; 32(5):565-71. PubMed ID: 1973085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502.
    Rasmussen C; Brownell J; Bergh T
    Acta Endocrinol (Copenh); 1991 Aug; 125(2):170-6. PubMed ID: 1680264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia.
    van der Heijden PF; de Wit W; Brownell J; Schoemaker J; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1991 Jul; 40(2):111-8. PubMed ID: 1676973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of CV205-502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine.
    Razzaq R; O'Halloran DJ; Beardwell CG; Shalet SM
    Horm Res; 1993; 39(5-6):218-22. PubMed ID: 7906243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
    Verhelst JA; Froud AL; Touzel R; Wass JA; Besser GM; Grossman AB
    Acta Endocrinol (Copenh); 1991 Oct; 125(4):385-91. PubMed ID: 1683503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CV 205-502--effectiveness, tolerability, and safety over 24-month study.
    Shoham Z; Homburg R; Jacobs HS
    Fertil Steril; 1991 Mar; 55(3):501-6. PubMed ID: 1672113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness, safety, and tolerability of CV 205-502 in hyperprolactinemic women: a 12-month study.
    van der Heijden PF; Lappöhn RE; Corbey RS; de Goeij WB; Brownell J; Rolland R
    Fertil Steril; 1989 Oct; 52(4):574-9. PubMed ID: 2806597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.
    Newman CB; Hurley AM; Kleinberg DL
    Clin Endocrinol (Oxf); 1989 Oct; 31(4):391-400. PubMed ID: 2576397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CV 205-502 treatment of macroprolactinomas.
    Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion.
    Rasmussen C; Bergh T; Wide L; Brownell J
    Clin Endocrinol (Oxf); 1987 Mar; 26(3):321-6. PubMed ID: 3308186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of two dopaminergic drugs on menstrual function and psychological state in hyperprolactinemia.
    Lappöhn RE; van de Wiel HB; Brownell J
    Fertil Steril; 1992 Aug; 58(2):321-7. PubMed ID: 1353028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
    Webster J
    Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group.
    Webster J; Piscitelli G; Polli A; D'Alberton A; Falsetti L; Ferrari C; Fioretti P; Giordano G; L'Hermite M; Ciccarelli E
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):323-9. PubMed ID: 7900937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin bioassay and hyperprolactinemia.
    Peabody CA; Schultz PN; Warner MD; Worsley IG; Friesen HG; Samaan NA
    J Endocrinol Invest; 1992; 15(7):497-9. PubMed ID: 1360020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states.
    Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Landi ML; Marzullo P; Panza N; Battista C; Lombardi G
    Biomed Pharmacother; 1994; 48(3-4):167-74. PubMed ID: 7993981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to the management of hyperprolactinemia.
    Philosophe R; Seibel MM
    Curr Opin Obstet Gynecol; 1991 Jun; 3(3):336-42. PubMed ID: 1687504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CV 205-502 treatment of hyperprolactinemia.
    Vance ML; Cragun JR; Reimnitz C; Chang RJ; Rashef E; Blackwell RE; Miller MM; Molitch ME
    J Clin Endocrinol Metab; 1989 Feb; 68(2):336-9. PubMed ID: 2521863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A; Halse J; Bakke S; Bjøro T; Hansen E; Djøseland O; Brownell J; Jervell J
    Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.